研究目的
To design a noninvasive method for monitoring oxygen changes during photodynamic therapy (PDT) to predict treatment response and optimize therapeutic protocols.
研究成果
The HMON-Ce6-[(Ru(dpp)3)]Cl2 nanosensor can effectively monitor oxygen consumption during PDT in real time, both in solution and cells, and shows potential for in vivo applications with good biocompatibility.
研究不足
The study primarily focuses on the proof-of-concept in vitro and preliminary in vivo results. Further studies are needed to optimize the nanosensor for clinical applications.
1：Experimental Design and Method Selection:
The study involves the synthesis of deformable hollow mesoporous organosilica nanoparticles (HMONs) and their modification to load oxygen-sensitive probe [(Ru(dpp)3)]Cl2 and photosensitizer chlorin e6 (Ce6).
2：6). Sample Selection and Data Sources:
2. Sample Selection and Data Sources: T98G cells and tumor-bearing nude mice were used as models.
3：List of Experimental Equipment and Materials:
Transmission electron microscopy (TEM), zeta potentials, hydrodynamic sizes, UV-vis spectra, nitrogen sorption isotherms, and fluorescence spectra were measured.
4：Experimental Procedures and Operational Workflow:
The HMONs were synthesized, loaded with [(Ru(dpp)3)]Cl2 and Ce6, and their oxygen detection ability was tested in vitro and in vivo.
5：Data Analysis Methods:
The fluorescence emission was recorded to quantify oxygen changes and ROS generation.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
